Jimandin

Sitagliptin, the active ingredient in Jimandin, is a DPP-4 inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adults by improving blood glucose control when used with diet and exercise. GNH USA supplies Jimandin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Jimandin (sitagliptin) belongs to the DPP‑4 inhibitor class and is used to manage hyperglycaemia in type 2 diabetes. - Type 2 diabetes mellitus: improves glycaemic control by increasing insulin secretion and decreasing glucagon release. - Adjunct to diet and exercise: helps patients achieve target HbA1c levels when lifestyle measures alone are insufficient. - Combination with metformin: provides additional glucose‑lowering effect for patients inadequately controlled on metformin alone.

Sitagliptin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea: mild to moderate discomfort in the stomach. - Headache: transient pain or pressure in the head. - Upper respiratory tract infection: symptoms such as sore throat, cough, or nasal congestion.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain that may indicate inflammation of the pancreas. - Severe allergic reactions: rash, itching, swelling, or difficulty breathing. - Joint pain: unexplained arthralgia that can be disabling. - Bullous pemphigoid: rare skin blistering disorder.

Before initiating Jimandin, clinicians should consider several safety aspects. - Renal function: assess eGFR and adjust dose in moderate to severe impairment. - Pancreatitis history: avoid use in patients with prior pancreatitis. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Elderly patients: monitor closely for dehydration and renal changes. - Concomitant medications: review for drugs that may affect glucose levels. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Sitagliptin may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Co‑administration with another DPP‑4 inhibitor (e.g., saxagliptin): duplicate pharmacologic effect. - Strong renal‑impairing agents in patients with eGFR <30 mL/min/1.73 m²: risk of accumulation.

Moderate Interactions (Monitor Closely): - Insulin or sulfonylureas: heightened risk of hypoglycaemia; dose adjustments may be needed. - Rifampin: may lower sitagliptin plasma concentrations, reducing effectiveness. - Diuretics: monitor electrolytes and renal function as volume changes can affect drug clearance.